Our client base consists of pubic traded companies in Europe, North America and Australia. The total universe of biotechnology companies that we follow on a daily basis comprises around 200 companies.
Please contact us if you are interested in research on either of these companies or on other companies in our universe.
Resverlogix (RVX.TO): Initiating Coverage Report
Resverlogix is a clinical stage cardiovascular company with an epigenetic platform technology that modulates protein production. The company is the first to test the BET inhibition hypothesis as a new approach for reducing major adverse cardiovascular events (MACE) in high risk diabetes and CKD patients.
Biofrontera (B8F.DE): Research Note
Biofrontera AG (B8F.DE, B8F.L) is a biopharmaceutical company specializing in the development of dermatological drugs. Its lead product is Ameluz®, a prescription drug approved for use in Europe for the treatment of mild to moderate actinic keratosis (AK) on the face and scalp in conjunction with photodynamic therapy (PDT).